Novo's EUR1.17 Billion Licensing Deal Sends Nanexa Stock Soaring

04:34 AM EDT, 09/25/2026 (MT Newswires) -- Shares in Nanexa (NANEXA.ST) skyrocketed on Friday morning after Danish pharmaceutical giant Novo (NOVO-B.CO) signed a 1.17 billion-euro licensing deal to use the Swedish company's drug delivery technology platform. Nanexa's shares were up more than 120% during early trading in Stockholm, while Novo stock was marginally higher in Copenhagen. The deal grants Novo a global exclusive license to use Nanexa's proprietary PharmaShell atomic layer deposition, or ALD, platform for certain therapeutic peptide drugs in indications including obesity, type 2 diabetes and other cardiometabolic diseases, according to a late Thursday announcement by Nanexa. Novo will lead the development and commercialization of up to five programs, exploring long-acting injectable formulations of its weight-loss and diabetes therapies with monthly and quarterly administration as target profiles. Nanexa will be eligible to receive an upfront payment of 615 million euros and additional consideration, subject to certain development, regulatory, and sales milestones, totaling up to 1.17 billion euros. It will also receive low single-digit royalties on global net sales of products developed under the agreement. We "look forward to working with [Novo] to successfully develop products with less frequent dosing in obesity and type 2 diabetes indications," Nanexa Chief Executive David Westberg said. Göran Ando, chairman of Nanexa, believes the financial strength gained through the Novo deal would help the company expand applications of the ALD technology and will allow it to "take new projects further in development before partnering which will generate financially very attractive potential future partner deals."